Publications 2021

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2021)
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Hemasphere, 5 (2), e528
DOI 10.1097/HS9.0000000000000528, PubMed 33554050

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2021)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^†
Ann Oncol, 32 (3), 309-322
DOI 10.1016/j.annonc.2020.11.014, PubMed 33549387

Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frølund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N (2021)
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
Eur J Haematol (in press)
DOI 10.1111/ejh.13709, PubMed 34536308

Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2021)
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 100 (1), 297-302
DOI 10.1007/s00277-020-04302-0, PubMed 33106909

Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC, Pauff JM, Kumar S (2021)
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Am J Hematol, 96 (4), 418-427
DOI 10.1002/ajh.26083, PubMed 33368455

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C et al. (2021)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Lancet Oncol, 22 (3), e105-e118
DOI 10.1016/S1470-2045(20)30756-7, PubMed 33662288

Richardson PG, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F, Le-Guennec S, Macé S, Dimopoulos MA (2021)
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study
Future Oncol
DOI 10.2217/fon-2021-0568, PubMed 34521277

Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R et al. (2021)
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Eur J Haematol
DOI 10.1111/ejh.13706, PubMed 34496096

Schjesvold F, Bringhen S, G Richardson P, Perrot A, Leleu X, Moreau P, A Dimopoulos M, Hulin C, Tekle C, Foster MC, Poole EM, van de Velde H, Facon T (2021)
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Am J Hematol, 96 (11), E423-E427
DOI 10.1002/ajh.26319, PubMed 34383345

Schjesvold F, Oriol A (2021)
Current and Novel Alkylators in Multiple Myeloma
Cancers (Basel), 13 (10)
DOI 10.3390/cancers13102465, PubMed 34070213

Schjesvold FH, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, van de Velde H, Bensfia S, Bringhen S (2021)
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Haematologica, 106 (4), 1182-1187
DOI 10.3324/haematol.2020.253450, PubMed 32586908

Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N, Bone Working Group of the International Myeloma Working Group (2021)
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
Lancet Oncol, 22 (3), e119-e130
DOI 10.1016/S1470-2045(20)30559-3, PubMed 33545067

Tjønnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
Monoklonal gammopati av klinisk betydning
Tidsskr Nor Laegeforen, 141 (2021-13)
DOI 10.4045/tidsskr.20.0981, PubMed 34596996

Publications 2020

Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2020)
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 99 (8), 1793-1804
DOI 10.1007/s00277-020-04149-5, PubMed 32613281

Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF et al. (2020)
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Lancet Oncol, 22 (1), 142-154
DOI 10.1016/S1470-2045(20)30680-X, PubMed 33301738

Oriol A, Larocca A, Leleu X, Hajek R, Hassoun H, Rodríguez-Otero P, Paner A, Schjesvold FH, Gullbo J, Richardson PG (2020)
Melflufen for relapsed and refractory multiple myeloma
Expert Opin Investig Drugs, 29 (10), 1069-1078
DOI 10.1080/13543784.2020.1808884, PubMed 32924646

Schjesvold F (2020)
Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019
Eur J Haematol, 105 (4), 434-448
DOI 10.1111/ejh.13464, PubMed 32557833

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos M (2020)
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
Eur J Haematol, 104 (5), 443-458
DOI 10.1111/ejh.13379, PubMed 31880006

Schjesvold F, Robak P, Pour L, Aschan J, Sonneveld P (2020)
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma
Future Oncol, 16 (11), 631-641
DOI 10.2217/fon-2020-0024, PubMed 32141766

Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B et al. (2020)
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Haematologica, 105 (12), 2879-2882
DOI 10.3324/haematol.2019.240374, PubMed 33256392

Publications 2019

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC, ICARIA-MM study group (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Lancet, 394 (10214), 2096-2107
DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H et al. (2019)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Lancet Oncol, 20 (6), e302-e312
DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P et al. (2019)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e459-e469
DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687

Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M et al. (2019)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Lancet Oncol, 20 (6), 781-794
DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405

Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J, KEYNOTE-185 Investigators (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e448-e458
DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689

Publications 2018

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R et al. (2018)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Lancet, 393 (10168), 253-264
DOI 10.1016/S0140-6736(18)33003-4, PubMed 30545780

Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18 (1), 801
DOI 10.1186/s12885-018-4722-x, PubMed 30089450

Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Schjesvold FH, Tjønnfjord GE, Munthe LA, Tasken K (2018)
In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
Blood, 132, 4676
DOI 10.1182/blood-2018-99-110357, PublikaID 304

Thimiri Govinda Raj DB, Giliberto M, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold FH, Munthe LA, Tasken K (2018)
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
DOI 10.1182/blood-2018-99-110669, PublikaID 303

Publications 2017

Schjesvold FH (2017)
Immunologiske mekanismer for drap av kreftceller
Tidsskr Nor Laegeforen, 137 (1), 58
DOI 10.4045/tidsskr.16.0963, PubMed 28073239

Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA (2017)
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
Leukemia, 31 (10), 2114-2121
DOI 10.1038/leu.2017.69, PubMed 28232741

Publications 2016

Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B (2015)
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
Cancer Res, 75 (16), 3268-78
DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231

Publications 2014

Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol, 5, 174
DOI 10.3389/fimmu.2014.00174, PubMed 24782871

Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B (2014)
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
Eur J Immunol, 44 (9), 2625-37
DOI 10.1002/eji.201444659, PubMed 24846412

Publications 2013

Schjesvold F, Wiencke K, Tjønnfjord GE (2013)
[Investigation of anemia]
Tidsskr Nor Laegeforen, 133 (6), 610
DOI 10.4045/tidsskr.13.0256, PubMed 23552139

Schjesvold FH (2013)
[Investigation of amyloidosis]
Tidsskr Nor Laegeforen, 133 (3), 266
DOI 10.4045/tidsskr.13.0044, PubMed 23381155

Publications 2012

Tazmini K, Bakken HN, Schjesvold FH (2012)
A woman in her seventies with reduced general condition, dyspnoea and generalised pain
Tidsskr Nor Laegeforen, 132 (17), 1969-72
DOI 10.4045/tidsskr.11.0608, PubMed 23007363

Publications 2009

Schjesvold FH (2009)
[Erythrocytosis as a problem]
Tidsskr Nor Laegeforen, 129 (22), 2387; author reply 2387
DOI 10.4045/tidsskr.09.1196, PubMed 19935946

Publications 2008

Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L (2008)
[High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
Tidsskr Nor Laegeforen, 128 (12), 1392-6
PubMed 18552900